Cargando…
SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma
Gemcitabine and cisplatin chemotherapy (GC regimen) represents a standard treatment for advanced urothelial carcinoma. We performed an open-label, single-arm, non-randomised, phase 2 trial evaluating the addition of sunitinib to standard GC chemotherapy (SGC regimen). Overall, 63 treatment-naïve par...
Autores principales: | Geldart, Thomas, Chester, John, Casbard, Angela, Crabb, Simon, Elliott, Tony, Protheroe, Andrew, Huddart, Robert A., Mead, Graham, Barber, Jim, Jones, Robert J., Smith, Joanna, Cowles, Robert, Evans, Jessica, Griffiths, Gareth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410296/ https://www.ncbi.nlm.nih.gov/pubmed/25465968 http://dx.doi.org/10.1016/j.eururo.2014.11.003 |
Ejemplares similares
-
A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)
por: Huddart, Robert A., et al.
Publicado: (2015) -
Introduction of Telemedicine During the COVID-19 Pandemic: A Challenge for Now, an Opportunity for the Future
por: Sosnowski, Roman, et al.
Publicado: (2020) -
Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic?
por: Novara, Giacomo, et al.
Publicado: (2020) -
Goldilocks and the BCG: Bacillus Calmette-Guérin Dose Reduction in the Age of Shortage
por: Nikas, Christine V., et al.
Publicado: (2020) -
Bladder Cancer Guidelines: Let Not the Cure Be Worse than the Disease
por: Kamat, Ashish M.
Publicado: (2021)